| Dr Richard Lussier Iii, DO | |
|
1215 Lee St, Charlottesville, VA 22908-1929 | |
| (434) 924-9400 | |
| (434) 982-1618 |
| Full Name | Dr Richard Lussier Iii |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 7 Years |
| Location | 1215 Lee St, Charlottesville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841722303 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 0102207155 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Novant Health Uva Health Haymarket Medical Center | Haymarket, VA | Hospital |
| Novant Prince William Medical Center | Manassas, VA | Hospital |
| Novant Health Uva Health System Culpeper Med Cente | Culpeper, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Virginia Imaging Llc | 2567479405 | 71 |
| Uva Community Health Medical Group, Llc | 4688587967 | 198 |
News Archive
About 30 million women in the U.S. have osteoporosis, with low bone mass and deteriorating bone structure that increases their risk for fractures. Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.
More than one million infants die each year because they are born too early, according to the just released White Paper, The Global and Regional Toll of Preterm Birth.
The novel coronavirus, now called the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), is the causative agent of the dreaded coronavirus disease (COVID-19). It was first discovered in Wuhan City, China, back in late December 2019 and has since then spread throughout the globe.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.
› Verified 2 days ago
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
About 30 million women in the U.S. have osteoporosis, with low bone mass and deteriorating bone structure that increases their risk for fractures. Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.
More than one million infants die each year because they are born too early, according to the just released White Paper, The Global and Regional Toll of Preterm Birth.
The novel coronavirus, now called the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), is the causative agent of the dreaded coronavirus disease (COVID-19). It was first discovered in Wuhan City, China, back in late December 2019 and has since then spread throughout the globe.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.
› Verified 2 days ago
| Entity Name | University Of Virginia Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720233596 PECOS PAC ID: 2567479405 Enrollment ID: O20090421000339 |
News Archive
About 30 million women in the U.S. have osteoporosis, with low bone mass and deteriorating bone structure that increases their risk for fractures. Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.
More than one million infants die each year because they are born too early, according to the just released White Paper, The Global and Regional Toll of Preterm Birth.
The novel coronavirus, now called the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), is the causative agent of the dreaded coronavirus disease (COVID-19). It was first discovered in Wuhan City, China, back in late December 2019 and has since then spread throughout the globe.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.
› Verified 2 days ago
| Entity Name | Uva Community Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023483567 PECOS PAC ID: 4688587967 Enrollment ID: O20110311000151 |
News Archive
About 30 million women in the U.S. have osteoporosis, with low bone mass and deteriorating bone structure that increases their risk for fractures. Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.
More than one million infants die each year because they are born too early, according to the just released White Paper, The Global and Regional Toll of Preterm Birth.
The novel coronavirus, now called the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), is the causative agent of the dreaded coronavirus disease (COVID-19). It was first discovered in Wuhan City, China, back in late December 2019 and has since then spread throughout the globe.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard Lussier Iii, DO Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Dr Richard Lussier Iii, DO 1215 Lee St, Charlottesville, VA 22908-1929 Ph: (434) 924-9400 |
News Archive
About 30 million women in the U.S. have osteoporosis, with low bone mass and deteriorating bone structure that increases their risk for fractures. Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.
More than one million infants die each year because they are born too early, according to the just released White Paper, The Global and Regional Toll of Preterm Birth.
The novel coronavirus, now called the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), is the causative agent of the dreaded coronavirus disease (COVID-19). It was first discovered in Wuhan City, China, back in late December 2019 and has since then spread throughout the globe.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.
› Verified 2 days ago
Dr. Norman A. Brenbridge, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 500 Martha Jefferson Dr, Charlottesville Radiology, Charlottesville, VA 22911 Phone: 434-244-4580 Fax: 434-244-4579 | |
Gia Ann Deangelis, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St Fl 1, Charlottesville, VA 22908 Phone: 434-924-2781 Fax: 434-982-1618 | |
Dr. Akhil Khetarpal, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St, Box 800719, Charlottesville, VA 22908 Phone: 434-924-2150 | |
Thomas J. Druzgal, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Lee St Fl 1, Charlottesville, VA 22908 Phone: 434-243-6888 Fax: 434-982-0943 | |
Rachita Khot, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 545 Ray C. Hunt Drive, Charlottesville, VA 22903 Phone: 434-982-0415 Fax: 434-243-6999 | |
Michael T. Perry, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-9400 Fax: 434-982-1618 | |
Dr. Colin P Derdeyn, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-9400 |